INTU	RMATION DISCLOSUR	ATTY. DOCK	ET NO.	Rec'd PCT/F	10 20	FEB. 2	<u>'UU1</u>
	CITATION			•		4	-6
		1331-334 APPLICANT		Unknown			-()
			OCTEL				pu
(U	se several sheets if necessary)	VON BOF	ASTEL	GROUP		<u> 10</u>	
				GROUP		10	400
		February	28, 2001				, (
XAMINER		U.S. P	ATENT DOCUMENTS				
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING	DATE
PL	5,470,838	11/1995	VAN BORSTEL) .,	GODOLAGO	II ALLE	·
	· ·						
		ļ <u> </u>					
		<u> </u>				<u> </u>	
		FOREIG	N PATENT DOCUMENTS				
		DATE				TRANS	LATION
	DOCUMENT	DATE	COLINTDY	01.400	011001400		
·	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		NO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		NO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		NO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		NO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		NO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS		NO
							NO
	OTHER DO	CUMENTS (include	ding Author, Title, Date, Per	tinent pages.	etc.)	YES	
2	OTHER DO	CUMENTS (include OP-Choline: Pharm	ding Author, Title, Date, Per nacoligical and Clinical Revie	tinent pages, o	etc.)	YES	
<u> </u>	OTHER DO SECADES et al.; "CD and Clinical Pharmac	CUMENTS (include OP-Choline: Pharm cology, 10/1995, V	ding Author, Title, Date, Per nacoligical and Clinical Revie ol. 17, Supplement 1, pp. 1-5	tinent pages, ow. Methods an	etc.)	YES	iment
2	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Van STN AN 9404969	ding Author, Title, Date, Per nacoligical and Clinical Revie /ol. 17, Supplement 1, pp. 1-5	tinent pages, ow. Methods and	etc.) d Findings i	in Exper	iment
2	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Value STN AN 9404969 all neuropathy: pre	ding Author, Title, Date, Pernacoligical and Clinical Revierol 17, Supplement 1, pp. 1-58, KEILBAUGH et al. Anti-huevention of 2', 3'-dideoxy cytic	tinent pages, ew. Methods and the state of t	etc.) d Findings i	in Exper	iment
2 0	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat	CUMENTS (include of the cology	ding Author, Title, Date, Pernacoligical and Clinical Revier of 17, Supplement 1, pp. 1-58, KEILBAUGH et al. Anti-huevention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993.	tinent pages, oww. Methods and Immunodo	etc.) d Findings i eficiency vire C 12 cells, a pp. 702-70 when expos	in Experus type a neurol	iment
2 2 P2	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol STN AN 9404969 all neuropathy: pred pyruvate. Moleculed cerebral and cerebral a	ding Author, Title, Date, Pernacoligical and Clinical Revier of 17, Supplement 1, pp. 1-58, KEILBAUGH et al. Anti-huevention of 2', 3'-dideoxy cyticular Pharmacology. 10/1993. Perebellar mitochondria productegeneration. Journal of Neuroscience	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	iment
2 P2	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol. STN AN 9404969 all neuropathy: pred pyruvate. Molecular decembers and coloratory-deficient here.	ding Author, Title, Date, Pernacoligical and Clinical Revie 701. 17, Supplement 1, pp. 1-5 18, KEILBAUGH et al. Anti-hub evention of 2', 3'-dideoxy cytical cular Pharmacology. 10/1993. Prebellar mitochondria product egeneration. Journal of Neuronal uman fibroblasts exhibiting de	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	iment
r Pr fl	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol. STN AN 9404969 all neuropathy: pred pyruvate. Molecular decembers and coloratory-deficient here.	ding Author, Title, Date, Pernacoligical and Clinical Revie 701. 17, Supplement 1, pp. 1-5 18, KEILBAUGH et al. Anti-hub evention of 2', 3'-dideoxy cytical cular Pharmacology. 10/1993. Prebellar mitochondria product egeneration. Journal of Neuronal uman fibroblasts exhibiting de	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	iment 1 nal evated
2 P2 PL	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol. STN AN 9404969 all neuropathy: pred pyruvate. Molecular decembers and coloratory-deficient here.	ding Author, Title, Date, Pernacoligical and Clinical Revie 701. 17, Supplement 1, pp. 1-5 18, KEILBAUGH et al. Anti-hub evention of 2', 3'-dideoxy cytical cular Pharmacology. 10/1993. Prebellar mitochondria product egeneration. Journal of Neuronal uman fibroblasts exhibiting de	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	iment 1 nal evated
2 P2 PL	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol. STN AN 9404969 all neuropathy: pred pyruvate. Molecular decembers and coloratory-deficient here.	ding Author, Title, Date, Pernacoligical and Clinical Revie 701. 17, Supplement 1, pp. 1-5 18, KEILBAUGH et al. Anti-hub evention of 2', 3'-dideoxy cytical cular Pharmacology. 10/1993. Prebellar mitochondria product egeneration. Journal of Neuronal uman fibroblasts exhibiting de	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	iment
2 P2 PL	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol. STN AN 9404969 all neuropathy: pred pyruvate. Molecular decembers and coloratory-deficient here.	ding Author, Title, Date, Pernacoligical and Clinical Revie 701. 17, Supplement 1, pp. 1-5 18, KEILBAUGH et al. Anti-hub evention of 2', 3'-dideoxy cytical cular Pharmacology. 10/1993. Prebellar mitochondria product egeneration. Journal of Neuronal uman fibroblasts exhibiting de	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	imenta 1 nal evated
2 f2 fL	OTHER DO SECADES et al.; "CE and Clinical Pharmac Database Medline on therapy and peripher model, by uridine and DYKENS, J.A. Isolat Ca2+ and Na+: Impli BODNAR et al. Resp	CUMENTS (include DP-Choline: Pharm cology. 10/1995, Vol. STN AN 9404969 all neuropathy: pred pyruvate. Molecular decembers and coloratory-deficient here.	ding Author, Title, Date, Pernacoligical and Clinical Revie 701. 17, Supplement 1, pp. 1-5 18, KEILBAUGH et al. Anti-hub evention of 2', 3'-dideoxy cytical cular Pharmacology. 10/1993. Prebellar mitochondria product egeneration. Journal of Neuronal uman fibroblasts exhibiting de	tinent pages, oww. Methods and standard immunodo dine toxicity in Pol. 44. No. 40 te free radicals rochemistry.	etc.) d Findings i eficiency viru C 12 cells, a pp. 702-70 when expos	in Experus type a neurolo6 sed to el	iment

INFOR	MATION DISCLOSURE	ATTY. DOC	KET NO.		SER	IAL NO.	F.		
	CITATION	1331-334	1		09/	763,955	₩.	_	- 1
	0	PAPLICANT					ří	Œ	1:1
		VON BO	DRSTEL				CENTER 1600/	C 1	$\tilde{\Omega}$
(Use	e several sheets if necessary [[] 1	7 200 LING DATE	Ē		GRO	OUP	33	9	111
		February	28, 200	1			90	2001	<
	DOCUMENT NUMBER	U.S.		OCUMENTS			SUBCLASS	91	П
XAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCHASS	FILIN IF APR	G DATE
PL	6,258,795	7/2001	VC	n Borstel et al					<u>ر ا</u>
7									
				 .					
+									-
		,							
						<u> </u>			
		EOREI	CN DATE	NT DOCUMENTS			<u>[</u>		
		FUNE	GNPAIL	NI DOCUMENTS				TRAN	SLATION
	DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	YES	NO
									ļ
									ļ
					110				-
									+
									+
									+
						+			-
	OTHER DOC	LIMENTS (incl	udina Aut	hor, Title, Date, F	Pertine	nt pages.	etc.)		٠,
	- Naviaux et al, "Clinica	experience wit	h uridine a	nd triacetyluridine	(PN40	1) therapy	of mitochor	ndrial d	iseáse
	abstract in meeting pro- Sofitel, Melbourne, Au	ogram for Mitoc	hondrial-D	ysfunction in Hum	an Pat	hology, Se	ptember 5-7	', 19 98	, Hôtel
					_		***		
				 					
					-				
			 						
									
xaminer	Name 1	end		Date Consider	ed	10-19	- 25		

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFOR	MATION DISCLOSUF	ATTY. DOCK	ÉT NO.	SERIAL NO.	CH CENTER TO	S.	,
• ,		4331-334 APPLICANT		09/763,955	CENA	3	令
		VON BO	RSTEL		· (E)	2002	` `
(Use	several sheets if necessary)	FILING DATE		GROUP	16	000	
		February	28, 2001 PATENT DOCUMENTS			300	
CAMINER						FILING	
VITIAL	DOCUMENT NUMBER 6,316,426	DATE 11/2001	NAME von Borstel et al	CLASS	SUBCLASS	<u>IF APPRO</u>)PR
	 						
							-
					:		
		-					
		-					
		FOREI	GN PATENT DOCUMENTS			TRANSL	ATI
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	
	OTHER DO	OCUMENTS (inclu	ıding Author, Title, Date, P nin Human Pathology confe	ertinent pages,	etc.) }ont-7-1 996		ón
	session, Melbourne	-Australia; particul	larly Dr. Naviaux's presentat	i on, second-one,	side A		
	December 28, 2001	Declaration of Wi	lliam L. Nyhan, M.D., Ph.D. i Plaintiff Pro Neuron Inc.'s N	n-Support of Defe Action for Prelimi	endant-The	Regents	-of_
	University or Californ	na's Opposition to	Plaintin Fromedion inc. 5 N	<u> </u>	iar y mijuricij	011.	
							—

Examiner: Initial it reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet	1 of 1	* 8					
INFOR	MATION DISCLOSURE	ATTY, DOCKET	NO.	SERIAL NO.		!· ,	
	CITATIONS (PE	1331-334		09/763,955	TEC) •	
	000	APPLICANT					Ш
	FEB 0 5 20	VON BOR	STEL		CEN	FEB	
" (Us	e several sheets if necessary)	VON BOR		GROUP	m	0	m
	ie several sheets (Loecessary)	February 2	8. 2001		ER 1600/290 290 SUBCLASS	~	\equiv
		U.S. PA	TENT DOCUMENTS		<u>§</u>	- S	$\overrightarrow{\Box}$
*EXAMINER				01.400	3 LIDOL 43	FILING	PATE.
INITIAL	4,960,759	DATE 10/1990	NAME De Luca et al	CLASS	SUBCLASS	IF APPRO	JKELA I E
12	4,000,700	10,1000	DO 2000 01 01				
					ļ		
					 		
			· · · · · · · · · · · · · · · · · · ·				
						•••	
						- N-14	
		·					
					<u> </u>		
-					 		
		FOREICI	N PATENT DOCUMENTS				
		FUREIGI	N PATENT DOCUMENTS			TRANSI	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
							-
					-	-	
	-				-		
	OTHER DOC	CUMENTS (includ	ling Author, Title, Date, P	ertinent pages,	etc.)		
						 	
		<u> </u>		1			
*Evaminar	Matrical		Date Considere	nd /n_1U -	2		
r* xairiiiier	JULATE A I	, , , , , , , , , , , , , , , , , , ,	i Date Considere	· · · · /// -/ -/ -/	<i>-</i> (

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet	1	f • 1			ĺ					
. INFO	RM.	ATION DISCLOSURE	ATTY. [OCKET NO.	Si	ERIAL N	10.			
		CITATION	<u>1331</u> -		0	9/763	,955			
•		יי מומי יי	APPLIC							
a	Jse s	everal sheets if necessary)	VON FILING	BORSTEL		DOLLD	·			
,		A TON THE OWNER OF THE OWNER OWNER OF THE OWNER OWNER OF THE OWNER OWNE			G	ROUP				
		everal sheets if necessary)		ary 28, 2001 I.S. PATENT DOCUM	ENTO					
*EXAMINER	_									DATE
INITIAL	<u> </u>	DOCUMENT NUMBER 60/121,588	DATE	NAM Naviaux, F	IE Robert K		LASS	SUBCLASS	IF APPR	<u>OPRIATE</u> 23/99 -
		00/121,000	···	Treeviolati, T						
								,		

	├					- K t	-Cl	EIVE) —	
				***			rrn (0 0 2002		
							רבט (2 0 2002		
-	ļ					TECH	CENT	ER 1600/2	900 -	
				·		ILVII	OLITI	LIT 1000/-		
		•								
	-						_			
	-									
			FO	REIGN PATENT DO	CUMENTS					
		DOCUMENT	DATE	COUN	TRY	С	LASS	SUBCLASS	TRANS YES	LATION NO
	-				.					
•										
	_									
	-									<u></u>
	l	OTHER DOCU	MENTS (including Author, Ti	tle. Date. Pertir	nent pa	ages. 6	etc.)		L .
4		December 9, 2001 Dect of California's Oppositio to Show Cause.	aration of	Robert Naviaux, M.D.	. in Support of E	Defend	ant-Th	e Regents of	of the Ur	niversit 1 Order
	\vdash									

Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

INFORI	MATION DISCLOSURE CITATION		DOCKET NO.		SERIAL NO. 09/763,95	REC	EIV	ED
100		APPLIC	334 CANT		09//63,93	C " NUL	2 4 20	02
, 7,		VON	BORSTEL					
2 9 2002	several sheets if necessary)	FILING			GROUP	TECH CEN	ER 160	10/2900
, and the second			uary 28, 2001					
EXAMINER			J.S. PATENT DOCU	MENTS			EII ING	DATE
INITIAL	DOCUMENT NUMBER	DATE	NA NA	ME	CLASS	SUBCLASS		
							,	
							\	
						EUE	VEL)
						MAY 3-0		
					TEC	CENTER	600/29	00
		FC	REIGN PATENT D	DCUMENTS			TRANS	LATION
	DOCUMENT	DATE	COU	NTRY	CLASS	SUBCLASS	YES	NO
		-=						
		-						<u> </u>
								-
	· · ·							–
	OTHER DOC	UMENTS (including Author,	itle, Date, Pe	rtinent pages,	etc.)		
	Letter dated July 27, 1	998 from F	lobert K. Navi a ux to	the U.S. Food	and Drug Adm	inistration-(F	DA)	
							-	
		<u> </u>						
			··			**		
Ever:		/_		to Considers	h D)	• 7		
Examiner	1///-//	- War	j Da	ite Considered	・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・	7 S		

Sheet 1	of 1	A ==== (=	OOKETNO	CEDIAL NO	RFC	EIVE
\ CIRFORM	ATION DISCLOSURE CITATION		OCKET NO.	SERIAL NO.		
ر د	CITATION	1331		09/763,955	SEP	1 8 2002
1 3 2002		APPLIC	ANT			
ŧ	· •		BORSTEL		TECH CEN	ITER 1600/2
(Use :	several sheets if necessary)	FILING	DATE	GROUP		
BADEMA		Febru	ary 28, 2001			
			S. PATENT DOCUMENTS	····		
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATI
						.
+						
<u> </u>						
<u>-</u>						
						· · ·
			DEION DATENT DOOUMENT			
** 		FC	REIGN PATENT DOCUMENT	<u> </u>		TRANSLATIC
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES NO
	OTUED DOC	IMPNITO /	naluding Author Title Date	Portinent pages	oto \	
	First Amended Cross-C	omplaint o	ncluding Author, Title, Date, if Defendants The Regents of t	he University of C	alifornia and	Dr. Robert h
	Naviaux; 07/26/02; pag	Jes 1-16.	aintiff-Wellstat-Therapeutics-Co			

*Examiner Date Considered D-/9-CD

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Shcet	1			/	70112			ī	귂	
INFO	RM#	isclosure ما الماد،		DOCKET NO.	APR 0 7 2003	SERIA				A R
		,,,,,,,,,	1331 APPLI	-334	à. 3	09//	63,955			
					BADEMARKS			Ţ		ς rπ
				BORSTE	L				<u>~</u> क—∵	203
(L	Jse sev	eral sheets if necessary)	FILING	DATE		GROU	Р		1600/	3 <u>m</u>
			February 28, 2001			1623	,		/290	
				IS DATENT	DOCUMENTS				8	
*EXAMINEI	٦			7.3. FATENI	DOCOMENTS					G DATE
INITIAL	1 1	DOCUMENT NUMBER	DATE	1	NAME		CLASS	SUBCLASS	IF APPR	OPRIATE
	+	6,472,378	10/2002		von Borstel					
· · · · · · · · · · · · · · · · · · ·	╌┼─┤									
	+				·					
	+-+									
	77									
			FOF	REIGN PATE	NT DOCUMENTS					<u>.</u>
		DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	TRANS YES	SLATION NO
	1 1	DOCUMENT	DATE	1	COUNTRY		CLASS	T	153	T 100
	++									
	+-+							1		+
	+									
	+									
		OTHER DOCL	JMENTS (ii	ncluding Au	thor, Title, Date, P	ertinent p	oages, e	tc.)		
		Copy of Current Claims	1 50; von B	orstel et al; Ap	pplication Serial No.	09/930,49	4; filed A	igust 16, 200	H; (Atto	rney
		Reference 1331-352).	1 10 00 40	1 45 46	D 1 A		-00/020	126 61-1 4		2001
		Copy of Current Claims (Attorney Reference 133)		-and-43-46; ve	en borster, App neatio	on Serrai in	0. 02/638	,130, 11160 A)111 20, 2	:001;···
Λ:		Morais, R., and Guertin,		Biochem., vol.	. 60, p. 290-294, 1982	2 "On the c	ontribution	on of the mite	ochondri	al
PL_		genome to the growth of								
· 1		Morias, R., et al, <u>In Vitro</u>				•	-	19-658, "Dev	elopmen	it and
		Characterization of Cont Bourgeron, Thomas, et a						1003 pp 10	360 103	76 "Fate
		and expression of the de								
.		virus-transformed lymph								
		Löffler, Monika, et al, M	solecular and	d Cellular Biod			'Dihydroo	orotat-ubiqui	none	
	ightarrow	oxidoreductase links mit								
		Page, Theodore, et al, Pr				1606, Octo	ber 1997.	"Developme	ental disc	order
		associated with increase Keilbaugh et al (Mol. Ph								
		Kralovansky et al, "Cand				-248, see a	bstract, li	nes 4-7 (199	3).	
		Lipp et al, Biology of the								
V		Sartori et al, Alcohol 3:9	7-100, see f	irst and last se	ntences of abstract (1	1986).				
-fL	\bot	Agnati et al, Acta Phys.	Scanda, 126	: 525-531, see	abstract, lines 5-15 ((1986).				
~	1 1									

*Examiner Date Considered /0-/4-03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

*Examiner

1331-334 APPLICANT VON BO FILING DATE February U.S. F	RSTEL	09/763,955 GROUP 1623			
VON BO FILING DATE February U.S. F	PATENT DOCUMENTS	GROUP			
FILING DATE February U.S. F	28, 2001 PATENT DOCUMENTS				
February U.S. F	28, 2001 PATENT DOCUMENTS				
U.S. F	PATENT DOCUMENTS	1623			
U.S. F	PATENT DOCUMENTS				
DATE					
	NAME			EII INI	DATE
10/1999		CLASS	SUBCLASS		
1	von Borstel et al.				
				-	
			<u> </u>		
				AP	Z
					严
<u> </u>			- 53	-35	-iii
			160	200	₹
			3/29	<u> </u>	Щ
			8		<u> </u>
FOREIG	N PATENT DOCUMENTS			TRANS	LATION
DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
					
	<u></u>				
	· · · · · · · · · · · · · · · · · · ·				
JMENTS (includ	ling Author, Title, Date, Pe	rtinent pages, et	lc.)		
nti-Human Immun	odeficiency Virus Nucleoside	Analogs on Mitoch		and Its	
Toxicity"; Molec	Pharmacol; 39:625-628; (199	1).	ronathy: Dra	vention	of 2' 3'
y in PC12 Cells, a	Neuronal Model, by Uridine a	and Pyruvate"; Mol	ec. Pharmaco	ol. 44:70	2-706
	JMENTS (includati-Human Immun Toxicity"; Molec.	JMENTS (including Author, Title, Date, Penti-Human Immunodeficiency Virus Nucleoside Toxicity"; Molec. Pharmacol; 39:625-628; (199) Juman Immunodeficiency Virus Type 1 Therapy	DATE COUNTRY CLASS DATE COUNTRY CLASS DIMENTS (including Author, Title, Date, Pertinent pages, et ati-Human Immunodeficiency Virus Nucleoside Analogs on Mitoch Toxicity"; Molec. Pharmacol; 39:625-628; (1991). Juman Immunodeficiency Virus Type 1 Therapy and Peripheral Neuronal Immunodeficiency Virus Type 1 Therapy Author Virus Type 1 Ther	DATE COUNTRY CLASS SUBCLASS CLASS SUBCLASS DIFFERENCE OF THE COUNTRY CLASS SUBCLASS DIFFERENCE OF THE COUNTRY CLASS SUBCLASS DIFFERENCE OF THE COUNTRY CLASS SUBCLASS DIFFERENCE OF THE COUNTRY CLASS SUBCLASS DIFFERENCE OF THE COUNTRY DIFFERENCE OF THE COU	FOREIGN PATENT DOCUMENTS DATE COUNTRY CLASS SUBCLASS YES UMENTS (including Author, Title, Date, Pertinent pages, etc.) nti-Human Immunodeficiency Virus Nucleoside Analogs on Mitochondrial DNA and Its

Examiner: Initial if reprence considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

INFORM	MAYON DISCLOSURE CITATION	ATTY. 1331	DOCKET NO. -334	SERIAL-70. 09/763,955	BECEIVED	
E		APPLIC	CANT	07/105,755	RECEIVED NAV 27 2003	
3 2003 Ey	several sheets if necessary)	VON BORSTEL FILING DATE GROUP			TECH CENTER 1600/290	
	se several sheets if necessary)		uary 28, 2001	1623	TECHUENT	
EMARK		L	J.S. PATENT DOCUMENTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	FILING DA SUBCLASS IF APPROPR	
	2002/0028787 A1	03/2002	Watkins et al			
			<u> </u>			
				:		
		-	-			

FOREIGN PATENT DOCUMENTS

TRANSLATION **DOCUMENT** DATE COUNTRY CLASS **SUBCLASS** YES NO WO 00/06174 02/2000 WIPO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

*Examiner

Date Considered

Examiner: Initial it beference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.